Drug intelligence / Profile preview

OL-108

Development stage: Phase 1
Lead developer: Overland Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

OL-108 is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Oricell Therapeutics. It is engineered to target the CD19 antigen, a protein expressed on the surface of B-lymphocytes. The therapy is designed to treat severe, relapsed, or refractory autoimmune diseases by depleting pathogenic B cells, which aims to reset the immune system and reduce the production of autoantibodies. OL-108 utilizes Oricell's proprietary Ori-CAR platform, which is designed to enhance the proportion of memory T cells and improve the persistence and efficacy of the CAR-T cells. It is currently being evaluated in clinical trials for several B-cell mediated autoimmune conditions, including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc), and ANCA-associated vasculitis (AAV).

Other names: OL-108OL108OL 108

Beyond the preview

Go deeper on OL-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OL-108.

Explore the full profile